Corporate Member Update- Jazz Pharmaceuticals
Corporate Member Update- Jazz Pharmaceuticals
ZIIHERA
June, 2025
Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC).
Read the full press release here.
